Renaissance Technologies LLC Purchases 19,700 Shares of Encompass Health Co. (NYSE:EHC)

Renaissance Technologies LLC boosted its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 63.1% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 50,900 shares of the company's stock after purchasing an additional 19,700 shares during the period. Renaissance Technologies LLC owned 0.05% of Encompass Health worth $4,701,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in EHC. MassMutual Private Wealth & Trust FSB boosted its position in Encompass Health by 87.8% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company's stock worth $27,000 after acquiring an additional 137 shares during the period. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Encompass Health by 38.7% during the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company's stock worth $42,000 after purchasing an additional 127 shares during the period. Tompkins Financial Corp purchased a new position in Encompass Health during the fourth quarter valued at approximately $46,000. V Square Quantitative Management LLC increased its stake in Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company's stock valued at $54,000 after buying an additional 177 shares during the period. Finally, Signaturefd LLC lifted its position in Encompass Health by 21.6% in the 4th quarter. Signaturefd LLC now owns 704 shares of the company's stock worth $65,000 after buying an additional 125 shares in the last quarter. 97.25% of the stock is owned by institutional investors and hedge funds.

Encompass Health Stock Performance

Shares of NYSE:EHC traded up $11.92 during midday trading on Friday, hitting $113.33. The company's stock had a trading volume of 2,076,448 shares, compared to its average volume of 675,826. Encompass Health Co. has a fifty-two week low of $82.09 and a fifty-two week high of $114.38. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.04 and a current ratio of 1.05. The stock has a market capitalization of $11.41 billion, a price-to-earnings ratio of 25.41, a PEG ratio of 2.31 and a beta of 0.87. The stock's 50 day simple moving average is $100.08 and its 200 day simple moving average is $98.51.

Encompass Health (NYSE:EHC - Get Free Report) last released its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.18. The business had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a net margin of 8.48% and a return on equity of 17.56%. As a group, research analysts anticipate that Encompass Health Co. will post 4.8 earnings per share for the current year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Tuesday, April 1st were paid a $0.17 dividend. The ex-dividend date of this dividend was Tuesday, April 1st. This represents a $0.68 dividend on an annualized basis and a yield of 0.60%. Encompass Health's payout ratio is currently 15.25%.

Analysts Set New Price Targets

EHC has been the topic of a number of research reports. Barclays upped their price target on shares of Encompass Health from $118.00 to $129.00 and gave the stock an "overweight" rating in a research note on Friday. KeyCorp raised their price target on Encompass Health from $120.00 to $122.00 and gave the stock an "overweight" rating in a research note on Friday. William Blair reissued an "outperform" rating on shares of Encompass Health in a research note on Friday, February 7th. StockNews.com raised shares of Encompass Health from a "hold" rating to a "buy" rating in a research report on Friday. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $110.00 target price on shares of Encompass Health in a research report on Tuesday, February 11th. Nine analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, Encompass Health has a consensus rating of "Buy" and a consensus target price of $110.88.

Insider Transactions at Encompass Health

In related news, CAO Andrew L. Price sold 5,042 shares of the firm's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the sale, the chief accounting officer now directly owns 69,164 shares of the company's stock, valued at $6,798,129.56. This trade represents a 6.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 2.10% of the stock is currently owned by insiders.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.